SEC Comment Letter 0000000000-24-007705 to NewAmsterdam Pharma Co N.V. (NAMS, NAMSW) (CIK 0001936258) (NAMS)
NewAmsterdam Pharma Co N.V. (NAMS, NAMSW) (CIK 0001936258)
Date: July 8, 2024 · CIK: 0001936258 · Accession: 0000000000-24-007705
AI Filing Summary & Sentiment
File numbers found in text: 333-280687
Letter
July 8, 2024 Michael Davidson Chief Executive Officer NewAmsterdam Pharma Co N.V. 20803 Biscayne Blvd, Suite #105 Aventura, FL 33180 Re:NewAmsterdam Pharma Co N.V. Registration Statement on Form S-3 Filed July 3, 2024 File No. 333-280687 Dear Michael Davidson: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jason Drory at 202-551-8342 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Brian K. Rosenzweig
Show Raw Text
July 8, 2024
Michael Davidson
Chief Executive Officer
NewAmsterdam Pharma Co N.V.
20803 Biscayne Blvd, Suite #105
Aventura, FL 33180
Re:NewAmsterdam Pharma Co N.V.
Registration Statement on Form S-3
Filed July 3, 2024
File No. 333-280687
Dear Michael Davidson:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that
the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jason Drory at 202-551-8342 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Brian K. Rosenzweig